Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 10/18/2017 5:08:16 AM - Followers: 723 - Board type: Free - Posts Today: 9

Innovation Pharmaceuticals Inc. (IPIX)

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564

About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at


Ongoing Human Trials:
Product Pipeline:





Recent News and Press Releases:

SEC Filings (CIK:0001355250):

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f

Share Structure:  See SEC filing link above for current share structure


Cellceutix IP - Patent Filings:


Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
External Links: USPTO, USPTO Assignment, Espacenet

Investor Relations:

Following is a DAILY chart:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/11/2017 06:04:37 AM
IPIX News: Statement of Changes in Beneficial Ownership (4) 09/06/2017 06:27:18 PM
#200267  Sticky Note Cellceutix Reports Very Encouraging Interim Analysis of Phase scottsmith 10/16/17 07:19:09 PM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#199632  Sticky Note FACT... $IPIX road to success with NO failed BooDog 10/10/17 04:26:14 PM
#198202  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A TheHound 09/26/17 02:43:47 PM
#197995  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/24/17 05:24:48 PM
#191428  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A LilBigKahuna 07/23/17 12:25:32 AM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#200482   "If Leo received the interim analysis, he has loanranger 10/18/17 05:08:16 AM
#200481   What trial are you talking about? Beth KarinCA 10/18/17 04:22:42 AM
#200480   Prurisol will capture at least 2/3 rds of georgejjl 10/18/17 04:00:23 AM
#200479   Brilacidin has been granted Fast Track by the georgejjl 10/18/17 03:52:58 AM
#200478   If a company tries a product and then Amatuer17 10/18/17 03:47:29 AM
#200477   Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Targets $1 Billion georgejjl 10/18/17 03:45:18 AM
#200476   Hasn’t Leo responded to many SH with same Amatuer17 10/18/17 03:41:49 AM
#200475   October 17, 2017 georgejjl 10/18/17 02:19:05 AM
#200474   If IPIX can't hold .63 this time, it's TheBunny 10/18/17 02:07:48 AM
#200473   The claim that Leo canceled P's interim analysis sox040713 10/17/17 09:43:52 PM
#200472   I certainly haven't forgotten the preliminary result for sox040713 10/17/17 09:25:14 PM
#200469   No...they gave him there opinions. What makes KarinCA 10/17/17 09:01:48 PM
#200467   It appears to me that he didn't unblind KarinCA 10/17/17 08:46:14 PM
#200466   The third reason in my mind could well 58nout 10/17/17 08:41:32 PM
#200465   You're right. It wouldn't have changed anything. But loanranger 10/17/17 08:29:13 PM
#200464   Hopefully he can air it out after the DaubersUP 10/17/17 08:27:13 PM
#200463   Possibly. I hope you are well JM. joseytheoutlawwales 10/17/17 08:19:24 PM
#200462   sad and pathetic To infinity and beyond! 10/17/17 08:17:06 PM
#200461   no one disagrees with this very simple and To infinity and beyond! 10/17/17 08:16:11 PM
#200460   Yep, would have been clearer if he said septmike09 10/17/17 08:15:48 PM
#200459   Kevetrin will be back in the drivers seat DaubersUP 10/17/17 08:12:27 PM
#200457   Thank you for the wonderful feedback as well tryz 10/17/17 08:09:02 PM
#200456   "I say he doesn't have the interim results loanranger 10/17/17 08:06:19 PM
#200455   Do not forget about Kevetrin. Please DaubersUP 10/17/17 08:04:44 PM
#200454   I guess the last patient for follow-up is ACanJadaS 10/17/17 07:58:45 PM
#200453   I'm not the one who kept on saying sox040713 10/17/17 07:46:43 PM
#200452   Hopefully they crunch that last data quick! Matagordaville 10/17/17 07:40:03 PM
#200451   next week is the final patient follow-up and TheHound 10/17/17 07:38:21 PM
#200450   I believe we have to wait for partnership groton68 10/17/17 07:28:23 PM
#200449   How do you know it is interested in Amatuer17 10/17/17 07:28:20 PM
#200448   Aspire is not in this for a few groton68 10/17/17 07:26:07 PM
#200447   I believe Aspire holds almost 5% of IPIX. septmike09 10/17/17 07:20:32 PM
#200446   Dana-Farber didn't drop K. After they hosted K sox040713 10/17/17 07:11:32 PM
#200445   That's a chance they're better. But we'll see. frrol 10/17/17 07:11:20 PM
#200444   Last year tax loss selling was used as sox040713 10/17/17 07:04:18 PM
#200443   A few things about Aspire. They're not manipulators. frrol 10/17/17 07:02:25 PM
#200442   Same here, non-issue. I think when Leo requested sox040713 10/17/17 06:56:45 PM
#200441   Now really, cancer treatment is 58nout 10/17/17 06:56:04 PM
#200440   With previous p53 drugs encountering serious side effects KarinCA 10/17/17 06:42:01 PM
#200439   Yes, while technically true. ;) He'd KarinCA 10/17/17 06:37:28 PM
#200438   yeah he really nailed it- other To infinity and beyond! 10/17/17 06:33:41 PM
#200437   Which brings it back to my question. How sox040713 10/17/17 06:31:10 PM
#200436   Thanks JUST 10-11-12 10/17/17 06:29:31 PM
#200435   I was talking about original K trial with Amatuer17 10/17/17 06:27:17 PM
#200434   New news blog out on IPIX website!!!... tryz 10/17/17 06:27:15 PM
#200433   As for the fundamentals and news for IPIX, BooDog 10/17/17 06:25:07 PM
#200431   The most recent short interest is < 1% sox040713 10/17/17 06:18:35 PM
#200428   I think we all expect good B OM To infinity and beyond! 10/17/17 06:16:42 PM
#200427   Your comment: noretreat 10/17/17 06:09:25 PM
#200426   How do you know Pfizer isn't one of sox040713 10/17/17 06:03:49 PM